# OnCo record keynote-170 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-170/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-170", "NCT02576990" ;
  schema:name "KEYNOTE-170"@en ;
  schema:description "KEYNOTE-170 showed that a PD-1 antibody works in primary mediastinal B-cell lymphoma, whose cells carry extra copies of the PD-L1 gene: almost half of heavily treated patients responded, which led to the first drug approval specific to this lymphoma."@en ;
  schema:url <https://onco.cc/trials/keynote-170/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02576990>, <https://doi.org/10.1200/JCO.19.01389> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/jak2/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> .